Study of a new cell therapy for synovial sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new cell therapy called TBI-1301 (Mip-cel) for people with synovial sarcoma that has spread or come back after chemotherapy. It is designed to help your immune system attack the cancer cells that have a specific marker (NY-ESO-1).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have a type of soft tissue cancer called synovial sarcoma
- Your tumor cannot be removed by surgery
- Your cancer has grown or come back after 1 to 4 rounds of chemotherapy (including a type called anthracycline)
- You have a specific immune system marker called HLA-A*02:01 or HLA-A*02:06
- Your tumor has a protein called NY-ESO-1 (tested in a lab)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of immune therapy using your own natural killer (NK) cells that are specially trained to find and attack cancer cells that have the NY-ESO-1 target. It is for people with certain sarcomas or other advanced solid tumors that have not responded to prior treatments.
This trial tests an engineered immune cell treatment (NY-ESO-1 TCR-T) for people with advanced soft tissue sarcoma that has returned or spread after standard treatment. It aims to treat cancer cells that show a specific marker (NY-ESO-1) in the tumor.
This trial tests a combination of two medicines: one that trains your immune cells to find cancer (ACTengine IMA203) and another that helps the body recognize the tumor (mRNA-4203). It's for people with advanced melanoma or synovial sarcoma who have already tried other treatments.
This study tests a customized immune-cell treatment made from your own T cells to attack cancers that have NY-ESO-1. It may help shrink tumors in people with metastatic or hard-to-treat cancer when other treatments have not worked.
This trial tests a drug called N-803 for people with synovial sarcoma or myxoid/round cell liposarcoma that has gotten worse after T-cell therapy. N-803 may help the immune system fight the cancer, and the study will see if it can slow or stop the cancer from growing.
This Phase 1 study tests a personalized immune therapy made from T cells to treat advanced solid cancers that carry a marker called NY-ESO-1. You may be able to join if your tumor shows the right NY-ESO-1 level and your body and lab tests can safely handle treatment.
Hear when a new Synovial Sarcomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.